Impax Laboratories Enters into Commercialization Agreement with Banner Pharmacaps
April 08 2011 - 8:00AM
Business Wire
Impax Laboratories, Inc. (NASDAQ: IPXL) today
announced that it will collaborate with Banner Pharmacaps Inc. with
respect to the supply and commercialization of two softgel capsule
products. The products and terms of the agreement were not
disclosed.
Larry Hsu, Ph.D., president and CEO of Impax Laboratories, said:
“We are excited to collaborate with Banner, a global leader in
developing and manufacturing softgel products. In less than a year,
we have entered into four distinct partnerships for alternate
dosage form products as we continue to execute our strategy of
diversifying our product base. Our business development activities
will continue to focus on delivering growth from high-value
products, technologies, and businesses in complementary dosage
forms.”
Roger E. Gordon, Ph.D., president and CEO of Banner Pharmacaps
Inc., added: “We are delighted to be joining forces with Impax, a
specialty pharmaceutical company whose vision and goals so closely
mirror those of Banner. They join our expanding list of partners
who look to Banner to provide expertise in the development of
gelatin-based drug delivery systems and unique technology
platforms.”
About Impax Laboratories, Inc.
Impax Laboratories, Inc. is a technology based specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of branded
products. Impax markets its generic products through its Global
Pharmaceuticals Division and markets third-party branded products
through the Impax Pharmaceuticals Division. Additionally, where
strategically appropriate, Impax has developed marketing
partnerships to fully leverage its technology platform. Impax
Laboratories is headquartered in Hayward, California, and has a
full range of capabilities in its Hayward, Philadelphia and Taiwan
facilities. For more information, please visit the Company's Web
site at: www.impaxlabs.com.
About Banner Pharmacaps Inc.
Banner Pharmacaps Inc. is a specialty pharmaceutical company
dedicated to the research, development, and manufacturing of unique
gelatin-based dosage forms. Banner has created proprietary drug
delivery platforms that enhance and control the absorption of
poorly soluble active pharmaceutical ingredients. Banner is
building a portfolio of Rx and OTC products that utilize these
innovative gelatin- and polymer-based technologies; and also
actively seeks to develop and market products through strategic
alliances and partnerships. Banner’s headquarters is located in
High Point, North Carolina, with additional research labs and
manufacturing facilities in The Netherlands, Canada, and Mexico.
Additional information is available on the website
www.banpharm.com.
The parent company of Banner Pharmacaps Inc. is VION N.V., an
international food group. VION has annual sales of more than € 9
billion and employs 27,000 people worldwide. The VION head office
is in Son, The Netherlands.
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995:
To the extent any statements made in this news release contain
information that is not historical, these statements are
forward-looking in nature and express the beliefs and expectations
of management. Such statements are based on current expectations
and involve a number of known and unknown risks and uncertainties
that could cause the Company’s future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Such risks and uncertainties include, but are not
limited to, the effect of current economic conditions on the
Company’s industry, business, financial position and results of
operations, the ability to maintain an effective system of internal
control over financial reporting, fluctuations in revenues and
operating income, the ability to successfully develop and
commercialize pharmaceutical products, reductions or loss of
business with any significant customer, the impact of competition,
the ability to sustain profitability and positive cash flows, any
delays or unanticipated expenses in connection with the operation
of the Taiwan facility, the effect of foreign economic, political,
legal and other risks on operations abroad, the uncertainty of
patent litigation, consumer acceptance and demand for new
pharmaceutical products, the difficulty of predicting Food and Drug
Administration filings and approvals, the inexperience of the
Company in conducting clinical trials and submitting new drug
applications, the ability to successfully conduct clinical trials,
reliance on alliance and collaboration agreements, the availability
of raw materials, the ability to comply with legal and regulatory
requirements governing the healthcare industry, the regulatory
environment, the ability to protect the Company’s intellectual
property, exposure to product liability claims and other risks
described in the Company’s periodic reports filed with the
Securities and Exchange Commission. Forward-looking statements
speak only as to the date on which they are made, and Impax
undertakes no obligation to update publicly or revise any
forward-looking statement, regardless of whether new information
becomes available, future developments occur or otherwise.
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From May 2024 to Jun 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jun 2023 to Jun 2024